{"name":"Multiple Sclerosis Center of Northeastern New York","slug":"multiple-sclerosis-center-of-northeastern-new-york","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"BG00012 (DMF) (Tecfidera®.)","genericName":"BG00012 (DMF) (Tecfidera®.)","slug":"bg00012-dmf-tecfidera","indication":"Relapsing-remitting multiple sclerosis (RRMS)","status":"marketed"},{"name":"incabotulinumtoxinA","genericName":"incabotulinumtoxinA","slug":"incabotulinumtoxina","indication":"Muscle spasticity associated with multiple sclerosis","status":"marketed"}]}],"pipeline":[{"name":"BG00012 (DMF) (Tecfidera®.)","genericName":"BG00012 (DMF) (Tecfidera®.)","slug":"bg00012-dmf-tecfidera","phase":"marketed","mechanism":"BG00012 (dimethyl fumarate) activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway to reduce oxidative stress and modulate immune responses in the central nervous system.","indications":["Relapsing-remitting multiple sclerosis (RRMS)","Secondary progressive multiple sclerosis (SPMS) with relapses"],"catalyst":""},{"name":"incabotulinumtoxinA","genericName":"incabotulinumtoxinA","slug":"incabotulinumtoxina","phase":"marketed","mechanism":"IncabotulinumtoxinA is a botulinum toxin type A that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.","indications":["Muscle spasticity associated with multiple sclerosis","Cervical dystonia","Blepharospasm","Hemifacial spasm"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOZ2dXd2pXUVM1eV9rRjU2X1FSeUtiUHJnUjFFR09oeHpDWWZOOFhQT1RXTTlsV2ZVbWhlU2k1TTNpTWxoQVlEVkIteDRmckZnUXVKTkhqOW9PcjVKR1hacHI3UnB2VnNwdDBzTV9tNGhBbER1eGwyaUY0S091YWp3UGNlR0VpWlFnNC00VER3S0JkaFd3dldGOGlxMFVtaVpZeEh2Y25KaExwWmEyZFZxTw?oc=5","date":"2023-10-26","type":"deal","source":"Bassett Healthcare Network","summary":"Bassett Healthcare Network Partnering with Geisinger on Plans to Open Specialty Pharmacy in 2024 - Bassett Healthcare Network","headline":"Bassett Healthcare Network Partnering with Geisinger on Plans to Open Specialty Pharmacy in 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE12Y0FtUzByR0tTbWFieWNpemd3NzEtNHQ4cWl1U2ZnQ3NVbHBoamVGaThVMFpSZ2JfVU9aYmZqVXhGMTZwTDRRVHdfMHQwNGR6X3d6N05NMEZtWnBTNDFqNQ?oc=5","date":"2019-09-27","type":"pipeline","source":"Science | AAAS","summary":"Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility - Science | AAAS","headline":"Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility - Science | AAAS","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}